Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charles David Jones is active.

Publication


Featured researches published by Charles David Jones.


Journal of Immunology | 2015

Conditional Deletion of NF-κB–Inducing Kinase (NIK) in Adult Mice Disrupts Mature B Cell Survival and Activation

Hans Brightbill; Janet Jackman; Eric Suto; Heather S. Kennedy; Charles David Jones; Sreedevi Chalasani; Zhonghua Lin; Lucinda Tam; Meron Roose-Girma; Mercedesz Balazs; Cary D. Austin; Wyne P. Lee; Lawren C. Wu

NF-κB–inducing kinase (NIK) is a primary regulator of the noncanonical NF-κB signaling pathway, which plays a vital role downstream of BAFF, CD40L, lymphotoxin, and other inflammatory mediators. Germline deletion or inactivation of NIK in mice results in the defective development of B cells and secondary lymphoid organs, but the role of NIK in adult animals has not been studied. To address this, we generated mice containing a conditional allele of NIK. Deletion of NIK in adult mice results in decreases in B cell populations in lymph nodes and spleen, similar to what is observed upon blockade of BAFF. Consistent with this, B cells from mice in which NIK is acutely deleted fail to respond to BAFF stimulation in vitro and in vivo. In addition, mice with induced NIK deletion exhibit a significant decrease in germinal center B cells and serum IgA, which is indicative of roles for NIK in additional pathways beyond BAFF signaling. Our conditional NIK-knockout mice may be broadly useful for assessing the postdevelopmental and cell-specific roles of NIK and the noncanonical NF-κB pathway in mice.


Proceedings of the National Academy of Sciences of the United States of America | 2015

Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells.

Anand K. Katakam; Hans Brightbill; Christian Franci; Chung Kung; Victor Nunez; Charles David Jones; Ivan Peng; Surinder Jeet; Lawren C. Wu; Ira Mellman; Lélia Delamarre; Cary D. Austin

Significance The noncanonical NF-κB signaling pathway via the serine kinase NIK (NF-κB–inducing kinase) is essential for normal immune system development and has been implicated in tumor cell survival and growth. Because NIK is under investigation as a therapeutic target, it is important to understand NIK’s role in the context of a fully developed immune system, particularly in regard to mounting adaptive T-cell responses. We have generated and characterized transgenic mice with conditionally deleted NIK in CD11c+ dendritic cells and observe impaired antigen cross-priming of a naive CD8 T-cell response. This defect results from defective antigen cross-presentation by CD8+ dendritic cells and also is associated with their reduced ability to secrete IL-12p40, a cytokine known to promote cross-priming in vivo. Dendritic cells (DCs) link innate and adaptive immunity and use a host of innate immune and inflammatory receptors to respond to pathogens and inflammatory stimuli. Although DC maturation via canonical NF-κB signaling is critical for many of these functions, the role of noncanonical NF-κB signaling via the serine/threonine kinase NIK (NF-κB–inducing kinase) remains unclear. Because NIK-deficient mice lack secondary lymphoid organs, we generated transgenic mice with targeted NIK deletion in CD11c+ cells. Although these mice exhibited normal lymphoid organs, they were defective in cross-priming naive CD8+ T cells following vaccination, even in the presence of anti-CD40 or polyinosinic:polycytidylic acid to induce DC maturation. This impairment reflected two intrinsic defects observed in splenic CD8+ DCs in vitro, namely antigen cross-presentation to CD8+ T cells and secretion of IL-12p40, a cytokine known to promote cross-priming in vivo. In contrast, antigen presentation to CD4+ T cells was not affected. These findings reveal that NIK, and thus probably the noncanonical NF-κB pathway, is critical to allow DCs to acquire the capacity to cross-present antigen and prime CD8 T cells after exposure to licensing stimuli, such as an agonistic anti-CD40 antibody or Toll-like receptor 3 ligand.


Journal of Histotechnology | 2013

Comparison of standard laminectomy with an optimized ejection method for the removal of spinal cords from rats and mice

Heather S. Kennedy; Charles David Jones; Patrick Caplazi

Abstract For researchers seeking to collect spinal cord samples from mice and rats while avoiding acid decalcification, few options are available. Laminectomy is the standard method which yields high quality samples, yet is time consuming and technically difficult. Ejection of the cord from the vertebral column is another technique commonly used; however, the literature suggests that this method can damage the spinal tissues and is typically avoided when histology of samples is the desired endpoint. Here, we describe an optimized method for ejection of spinal cords from rats and mice, and compare histological quality of these samples with those collected via laminectomy. Our results show that ejection can yield high quality spinal cord samples and may be suitable for use as an alternative to laminectomy.


Proceedings of the National Academy of Sciences of the United States of America | 1997

Molecular determinants of tissue selectivity in estrogen receptor modulators

Timothy Alan Grese; James P. Sluka; Henry U. Bryant; George Joseph Cullinan; Andrew Lawrence Glasebrook; Charles David Jones; Ken Matsumoto; Alan David Palkowitz; Masahiko Sato; John David Termine; Mark Alan Winter; Na N. Yang; Jeffrey Alan Dodge


Journal of Medicinal Chemistry | 1997

Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene

Timothy Alan Grese; Stephen Cho; Don Richard Finley; Alexander G. Godfrey; Charles David Jones; Charles Willis Lugar; Michael J. Martin; Ken Matsumoto; Lewis D. Pennington; Mark Alan Winter; M. Dee Adrian; Harlan W. Cole; David E. Magee; D. Lynn Phillips; Ellen R. Rowley; Lorri L. Short; and Andrew L. Glasebrook; Henry Uhlman Bryant


Archive | 1998

Selective .beta.3 adrenergic agonists

Thomas Allan Crowell; Charles David Jones; Anthony J. Shuker


Archive | 1996

Benzothiophenes with novel basic side chains

Jeffrey Alan Dodge; Charles David Jones; Tokarz Michelle Lee Bourgeois


Archive | 2002

Selective B3 adrenergic agonists

Thomas Alan Crowell; Deborah Ann Evrard; Charles David Jones; Brian Stephen Muehl; Christopher John Rito; Anthony J. Shuker; Andrew John Thorpe; Kenneth Jeff Thrasher


Archive | 2001

Compuestos de benzotiofeno.

Charles David Jones; Alan David Palkowitz; Kenneth Jeff Thrasher


Archive | 1998

Compositions for use in inhibiting uterine fibrosis

Larry John Black; George Joseph Cullinan; Charles David Jones; Michael W. Draper; David Edward Seyler

Collaboration


Dive into the Charles David Jones's collaboration.

Top Co-Authors

Avatar

Henry Uhlman Bryant

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James E. Audia

University of South Carolina

View shared research outputs
Researchain Logo
Decentralizing Knowledge